bioMérieux's consolidated sales reached 2,668 million euros at September 30, 2023, compared with 2,560 million euros at September 30, 2022, representing reported growth of +4.2%. Organic growth, excluding currency and scope effects, reached +8.0% for the first 9 months of the year.

In Clinical Applications, which account for around 84% of the Group's total cumulative sales, sales in Q3 2023 were up 7% on Q3 2022

Sales in Industrial Applications, which account for around 16% of the Group's sales, were up by more than 6%, reaching almost 138 million euros at the end of Q3 2023.

The Group confirms its 2023 targets. It expects organic sales growth of between +4% and +6% and a contribution margin of between €600 million and €630 million.

Copyright (c) 2023 CercleFinance.com. All rights reserved.